{"filing":{"accession_number":"0001193125-26-399545","cik":"0001671584","ticker":"APVO","company_name":"Aptevo Therapeutics Inc.","form":"8-K","filing_date":"2026-09-23","report_date":"2026-09-22","primary_document":"apvo-20260922.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1671584/000119312526399545/apvo-20260922.htm"},"events":[{"id":34640,"run_id":31881,"accession_number":"0001193125-26-399545","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"This is a clear disclosure of shareholder voting results from a Special Meeting held on September 22, 2026. The filing reports final voting tallies for four proposals: amendment to Certificate of Incorporation (not approved), issuance of common stock exceeding 20% (approved), Fifth Amended and Restated 2018 Stock Incentive Plan (approved), and authorization to adjourn (approved). The approval of Proposal 2 regarding dilutive issuance of common stock and the stock incentive plan are material to investors' assessment of capital structure and equity dilution.","company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","filing_date":"2026-09-23","form":"8-K","submitted_at":null,"items":[{"id":38433,"accession_number":"0001193125-26-399545","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This is a clear disclosure of shareholder voting results from a Special Meeting held on September 22, 2026. The filing reports final voting tallies for four proposals: amendment to Certificate of Incorporation (not approved), issuance of common stock exceeding 20% (approved), Fifth Amended and Restated 2018 Stock Incentive Plan (approved), and authorization to adjourn (approved). The approval of Proposal 2 regarding dilutive issuance of common stock and the stock incentive plan are material to investors' assessment of capital structure and equity dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T20:44:44.959110+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38433,"accession_number":"0001193125-26-399545","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This is a clear disclosure of shareholder voting results from a Special Meeting held on September 22, 2026. The filing reports final voting tallies for four proposals: amendment to Certificate of Incorporation (not approved), issuance of common stock exceeding 20% (approved), Fifth Amended and Restated 2018 Stock Incentive Plan (approved), and authorization to adjourn (approved). The approval of Proposal 2 regarding dilutive issuance of common stock and the stock incentive plan are material to investors' assessment of capital structure and equity dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T20:44:44.959110+00:00","company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","filing_date":"2026-09-23"}]}